Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0816 • ACR Convergence 2020
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
Jakub Závada¹ and Lucie Nekvindova², ¹Revmatologický ústav, Praha 2, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…
Abstract Number: 1014 • ACR Convergence 2020
Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years
John Hanly¹ and Lynn Lethbridge², ¹Dalhousie University, Halifax, NS, Canada, ²Dalhousie University, Halifax, Canada
Background/Purpose: The objective of the current study was to examine the change in prescribing patterns for older adults with RA over a 20 year period…
Abstract Number: 1357 • ACR Convergence 2020
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
Adela Castro¹, Jesus Diaz², Guillermo Quiceno³ and John Cush⁴, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX, ⁴University of Texas Southwestern Medical School, Dallas, TX
Background/Purpose: Active ankylosing spondylitis (AS) has been associated with poor quality of life and work disability in up to 50% of patients (1). There is…
Abstract Number: 1758 • ACR Convergence 2020
Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Jenya Antonova², Lawrence Chang², Suying Li³, Haifeng Guo³, Yuanyuan Ji³ and Mark Genovese⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
Abstract Number: 0003 • ACR Convergence 2020
Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations
Quinn Pritchett¹, Rebecca Overbury¹, Dorota Lebiedz-Odrobina¹, Julie Thomas¹, Tawnie Braaten², Stacey Clardy¹, Marc Elgort³, Emily Spivak¹, Patricia Slev³, Lisa Peterson³ and Tracy Frech⁴, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, ³ARUP, Salt Lake City, UT, ⁴University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic is especially terrifying for patients on immunosuppression for autoimmune disease. With the exception of social isolation, experts do not have clear…
Abstract Number: 0226 • ACR Convergence 2020
Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis
Gerd Burmester¹, Vivian Bykerk², Maya Buch³, Yoshiya Tanaka⁴, Hideto Kameda⁵, Amy Praestgaard⁶, Hubert van Hoogstraten⁷, Antonio Fernandez-Nebro⁸ and Thomas Huizinga⁹, ¹Charité University Hospital Berlin, Berlin, Germany, ²Hospital for Special Surgery, New York, NY, ³Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Toho University, Tokyo, Japan, ⁶Sanofi, Cambridge, MA, ⁷Sanofi, Bridgewater, NJ, ⁸University of Malaga, Malaga, Spain, ⁹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs like methotrexate (MTX) has demonstrated improvement in symptomatic and functional outcomes in patients (pts)…
Abstract Number: 0504 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Mark Genovese¹, Apinya Lertratanakul², Jaclyn K Anderson², Kim Papp³, William Tillett⁴, Filip Van den Bosch⁵, Shigeyoshi Tsuji⁶, Eva Dokoupilova⁷, Mauro Keiserman⁸, Xin Wang², Sheng Zhong², Patrick Zueger², Aileen Pangan⁹ and Philip Mease¹⁰, ¹Stanford University Medical Center, Palo Alto, CA, ²AbbVie Inc., North Chicago, IL, ³Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁷Uherske Hradiste and University of Veterinary and Pharmaceutical Sciences,, Brno, Czech Republic, ⁸Pontificial Catholic University, Porto Alegre, Brazil, ⁹Abbvie Inc., La Grange, IL, ¹⁰Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment…
Abstract Number: 0817 • ACR Convergence 2020
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
Geoffrey Littlejohn¹, Tegan Smith², Kathleen Tymms³, Peter Youssef⁴, Helen Cooley⁵, Sabina Ciciriello⁶, David Mathers⁷, Catherine OSullivan² and Hedley Griffiths⁸, ¹Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁴University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, ⁵Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁶Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ⁷Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁸Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia
Background/Purpose: JAK inhibitors (JAKi) are targeted synthetic DMARDs (tsDMARDs) with a different mode of action (MOA) to conventional synthetic and biologic DMARDs (cs and bDMARDs).…
Abstract Number: 1015 • ACR Convergence 2020
The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)
Chou Luan Tan¹, Boon Han Ng², Noor Shahrazat Ahmad², Shahrul Aiman Soelar², Muhammad Zulhilmi Asyraf Jazlan², Mohd Ammar Dzakirin Md Mansor², Mohd Azri Mohd Suan², Kuang Kiat Kiew², Zalwani Zainuddin², Muhammad Radzi Abu Hassan² and Chong Hong Lim², ¹Hospital Sultanah Bahiyah, Kementerian Kesihatan Malaysia, Alor Setar, Kedah, Malaysia, ²Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia
Background/Purpose: Majority of DMARDs, including methotrexate (MTX), leflunomide (LEF) and sulfasalazine (SSZ) arebelieved to be hepatotoxic, causing liver fibrosis. However, the clinical findings were inconsistent.…
Abstract Number: 1360 • ACR Convergence 2020
New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study
Jean-Guillaume Letarouilly¹, Benjamin Pariente², Thao Pham³, Emilie Acquacalda⁴, Béatrice Banneville⁵, Sébastien Barbarot⁶, Elodie Bauer⁷, Pauline Baudart⁸, Pascal Claudepierre⁹, Arnaud Constantin¹⁰, Emmanuelle Dernis¹¹, Renaud Felten¹², Philippe Gaudin¹³, Céline Girard¹⁴, Bruno Gombert¹⁵, Philippe Goupille¹⁶, Xavier Guennoc¹⁷, Isabelle Henry-Desailly¹⁸, Denis Jullien¹⁹, Elena Karimova²⁰, Sylvain Lanot²¹, Loïc Le Dantec²², Tristan Pascart²³, Laurianne Plastaras²⁴, Nathalie Sultan-Bichat²⁵, Xavier Truchet²⁶, Stéphane Varin²⁷, Daniel Wendling²⁸, Lousie Gaboriau²⁹, Delphine Staumont-Sallé³⁰, Laurent Peyrin-Biroulet³¹ and René-Marc Flipo¹, ¹Univ-Lille, CHU Lille, department of rheumatology, Lille, France, ²Univ-Lille, CHU Lille, department of gastroenterology, Lille, France, ³Aix Marseille Univ, APHM, department of rheumatology, Marseille, France, ⁴CHPG, department of rheumatology, Monaco, Monaco, ⁵AP-HP, Hôpital Pitié-Salpêtrière, Service de Rhumatologie, Paris, 75013, Paris, France, ⁶CHU de Nantes, department of dermatology, Nantes, France, ⁷CHRU Nancy, department of rheumatology, VANDOEUVRE LES NANCY, Lorraine, France, ⁸CHU Caen, department of rheumatology, Caen, France, ⁹Hôpital Henri Mondor, Université Paris Est Créteil, EA 7379 EpiDermE, department of rheumatology, Créteil, France, ¹⁰Hospital Pierre Paul Riquet, Toulouse, France, ¹¹CH Le Mans, department of rheumatology, Le Mans, France, ¹²Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, ¹³CHU Grenoble, department of rheumatology, Grenoble, France, ¹⁴CHU Montpellier, department of rheumatology, Montpellier, France, ¹⁵CH La Rochelle, department of rheumatology, La Rochelle, France, ¹⁶CHU Tours, department of rheumatology, Tours, France, ¹⁷CH Saint-Brieuc, department of rheumatology, Saint-Brieuc, France, ¹⁸CHU Amiens, department of rheumatology, Amiens, France, ¹⁹CHU Lyon, department of dermatology, Lyon, France, ²⁰CH Lens, department of dermatology, Lens, France, ²¹CH Alençon, department of rheumatology, Alençon, France, ²²Ahnac, department of rheumatology, Hénin-Beaumont, France, ²³Ghicl, Hôpital Saint-Philibert, department of rheumatology, Lomme, France, ²⁴CH Colmar, department of gastroenterology, Colmar, France, ²⁵CH Ouest-Réunion, department of dermatology, Saint Paul, La Réunion, France, ²⁶HIA Sainte-Anne, department of gastroenterology, Toulon, France, ²⁷CHD Vendée, department of rheumatology, La Roche-sur-Yon, France, ²⁸CHU Besançon, department of rheumatology, Besancon, France, ²⁹Univ-Lille, CHU Lille, department of pharmacovigilance, Lille, France, ³⁰Univ-Lille, CHU Lille, department of dermatology, Lille, France, ³¹CHU Nancy, department of gastroenterology, VANDOEUVRE LES NANCY, Lorraine, France
Background/Purpose: A warning regarding safety of Interleukin 17 inhibitors (IL-17i) has been issued from data of randomized controlled trials (RCT) showing cases of new-onset inflammatory bowel…
Abstract Number: 1763 • ACR Convergence 2020
Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis
Robert Landewé¹, Daniel H Solomon², Gianluca Bonfanti³, Luigi Manca³, John C Woolcott⁴, Jasper Deuring⁵, Stephen Watt⁶, Pritha Bhadra Brown⁶, Rebecca Germino⁶, Birol Emir⁶ and Roger A Edwards⁷, ¹Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ²Brigham and Women's Hospital, Boston, MA, ³Fair Dynamics Consulting, SRL, Milan, Italy, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Rotterdam, Netherlands, ⁶Pfizer Inc, New York, NY, ⁷Health Services Consulting Corporation, Boxborough, MA
Background/Purpose: Patients with RA exhibit wide variations in response to therapy. Early treatment response profiles may help us to better predict subsequent treatment response, thus…
Abstract Number: 0005 • ACR Convergence 2020
Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists
Bella Mehta¹, Deanna Jannat-Khah², Carol Mancuso³, Anne Bass¹, Carine Moezinia⁴, Allan Gibofsky³, Susan Goodman⁵ and Said Ibrahim⁶, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York City, NY, ³Hospital for Special Surgery, New York City, ⁴Hospital for Special Surgery, New York, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁶Weill Cornell Medicine, Cleveland, OH
Background/Purpose: To investigate the perceptions and behaviors of rheumatologists in the United States (US) regarding the risk of COVID-19 for their autoimmune patients and the…
Abstract Number: 0229 • ACR Convergence 2020
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years
Kevin Winthrop¹, Yoshiya Tanaka², Tsutomu Takeuchi³, Alan Kivitz⁴, Franziska Matzkies⁵, Mark Genovese⁵, Deyuan Jiang⁵, Kun Chen⁵, Beatrix Bartok⁵, Angelika Jahreis⁵, Robin Besuyen⁶, Gerd Burmester⁷ and Jacques-Eric Gottenberg⁸, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁴Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos BV, Leiden, Netherlands, ⁷Charité University Hospital Berlin, Berlin, Germany, ⁸Strasbourg University Hospital, Strasbourg, France
Background/Purpose: The oral, selective Janus kinase-1 inhibitor filgotinib (FIL) significantly improved RA signs and symptoms in patients (pts) with MTX-naïve and MTX- and biologic-refractory RA.1–5…
Abstract Number: 0578 • ACR Convergence 2020
Going Digital Due to COVID 19 Crisis: A Rapid Reorganisation of Medication Clinics
Rian Penford¹, Angela Reith¹, Elaine Wren¹ and Kirsten Mackay¹, ¹Torbay and South Devon NHS Foundation Trust, Torquay, United Kingdom
Background/Purpose: Until the COVID 19 crisis we initiated DMARD(s) and Biologic therapies using shared medical clinics. More than 30 patients could seen per week, with…
Abstract Number: 0825 • ACR Convergence 2020
Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials
Niall Jones¹, Vibeke Strand², Hendrik Schulze-Koops³, Eduardo Mysler⁴, Cassandra D Kinch⁵, David Gruben⁶, Rebecca Germino⁷, Carol A Connell⁶ and Lihi Eder⁸, ¹Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ⁴Organización Médica de Investigación, Buenos Aires, Argentina, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY, ⁸Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Differences in efficacy outcomes favoring male vs female patients (pts) with RA have been reported with csDMARDs1 and TNF inhibitors;2 results with JAK inhibitors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].